
June 2026
Through a collaboration between Providence Cancer Institute and Microsoft, patients are benefiting from a groundbreaking artificial intelligence tool called GigaPath. This innovation uses routine pathology images — known as hematoxylin and eosin (H&E) slides — to help identify genetic changes in cancer.
Traditionally, detecting these mutations can require additional testing and time. GigaPath offers a new approach by predicting actionable mutations directly from existing images.
Turning insights into treatment
By identifying mutations earlier, care teams can make more informed decisions about targeted therapies — helping match patients to treatments designed for their specific cancer.
This approach supports more personalized care, giving patients access to therapies that may improve outcomes while reducing delays.
By integrating artificial intelligence into routine clinical workflows, we’re helping bring leading-edge innovation directly to the bedside.





















